The Dog Aging Project has made national headlines in scientific and popular media for its innovative approach to understanding human aging by studying canine longevity.
Led by Matt Kaeberlein, Ph.D., Co-director, University of Washington Medicine Nathan Shock Center of Excellence in the Basic Biology of Aging, The Dog Aging Project aims to identify the genetic and environmental factors that underlie healthy aging to develop therapies--such as the use of the FDA-approved drug Rapamycin-- that extend healthy lifespan.
In this webinar geared for both the general public and research community, Dr. Kaeberlein will share updates on the Dog Aging Project’s key research:
•A Longitudinal study, where individual animals will be followed throughout life to understand the biological and environmental factors that determine why some dogs die early or succumb to diseases such as cancer, kidney failure, and dementia, while others live to a relatively old age free from these problems;
•Trial One Study with Rapamycin, which expanded on studies in older mice and looked for improvements in heart function in the dogs that received rapamycin relative to those that received a placebo;
•Trial Two Study with Rapamycin, which is currently enrolling a second cohort of middle-aged dogs into a longer-term, low-dose rapamycin regimen designed to maximize lifespan and healthspan extension. Several age-related parameters will be assessed before, during, and after the treatment period, including cognitive function, heart function, and activity.
The webinar will include a 20-minute presentation followed by Q&A, facilitated by Steven N. Austad, Ph.D., Co Principal Investigator of the Nathan Shock Centers Coordinating Center and Director of the Nathan Shock Center at the University of Alabama Birmingham.
Presented by the Nathan Shock Centers Coordinating Center and the University of Washington Nathan Shock Center.
